List of Excipients in Branded Drug LIORESAL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Saol Therapeutics Inc	LIORESAL (BACLOFEN)	baclofen	70257-560	SODIUM CHLORIDE
Saol Therapeutics Inc	LIORESAL (BACLOFEN)	baclofen	70257-560	WATER

Lioresal Excipient Strategy and Commercial Opportunities for Baclofen Products

Last updated: October 13, 2026

Lioresal is the branded formulation of baclofen, a small-molecule gamma-aminobutyric acid B receptor agonist used for spasticity. Its core compound and conventional oral dosage form are long off-patent. Commercial opportunity therefore depends on formulation performance, supply reliability, patient adherence, differentiated delivery, and regulatory execution rather than protection of the baclofen molecule.

The strongest opportunities are in oral liquids, pediatric and geriatric dosage forms, preservative-controlled products, orally disintegrating tablets, modified-release systems, and intrathecal delivery components. The principal commercial constraint is that baclofen is inexpensive, widely available, and clinically familiar.

What is Lioresal and which baclofen formulations are commercially relevant?

Lioresal contains baclofen, a centrally acting skeletal muscle relaxant. In the United States, baclofen is available primarily as oral tablets, oral solutions, and intrathecal injection products. Lioresal Intrathecal is administered through an implantable pump for severe spasticity when oral therapy is ineffective or poorly tolerated [1].

Product category	Active ingredient	Typical route	Primary use	Commercial status
Lioresal oral tablets	Baclofen	Oral	Spasticity	Generic competition
Baclofen tablets	Baclofen	Oral	Spasticity	Multiple generic suppliers
Baclofen oral solution	Baclofen	Oral	Patients unable to swallow tablets	Smaller but differentiated market
Lioresal Intrathecal	Baclofen	Intrathecal	Severe spasticity	Specialist, device-linked market
Generic intrathecal baclofen	Baclofen	Intrathecal	Severe spasticity	Competition varies by jurisdiction

The oral product is typically supplied in 5 mg, 10 mg, and 20 mg strengths. Intrathecal products use highly dilute sterile baclofen solutions intended for pump administration, with concentration selected according to the pump system and clinical regimen [1, 2].

What excipients are used in Lioresal and baclofen products?

The exact excipient composition depends on the manufacturer, dosage form, strength, and jurisdiction. Product labeling should control over secondary databases because excipient systems can change after formulation amendments.

Oral tablets

Lioresal and generic baclofen tablets generally use conventional solid-dose excipients such as:

• Lactose or another water-soluble diluent
• Microcrystalline cellulose
• Pregelatinized starch or starch
• Povidone or another binder
• Crospovidone or croscarmellose sodium as a disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Film-coating polymers, pigments, and plasticizers where applicable

The most commercially important excipient questions are not whether an excipient is novel. They are whether the product is lactose-free, low-sodium, gluten-free, suitable for pediatric patients, compatible with automated manufacturing, and robust across dose strengths.

Oral liquid products

Baclofen oral solutions and suspensions require a more complex excipient system. The formulation may include:

• Purified water
• Buffering agents
• Sweeteners
• Flavors
• Viscosity modifiers
• Wetting or suspending agents
• Preservatives, where required
• Chelating agents or antioxidants where justified by stability data

A liquid formulation must control potency, microbial quality, palatability, sedimentation or precipitation, dosing accuracy, and container compatibility. Products that use a unit-dose cup, oral syringe, or adapter can create practical differentiation without changing the active ingredient.

Intrathecal injection

Intrathecal baclofen requires a sterile, injectable formulation with tight control over particulate matter, endotoxin, sterility, pH, osmolality, extractables, leachables, and container closure integrity. The excipient system is intentionally limited. Sodium chloride and water for injection are typical formulation components for parenteral baclofen products, but the approved labeling for the specific product must be used to confirm composition [1, 2].

Intrathecal formulations face a higher technical barrier than tablets because the product is delivered directly into the central nervous system. Preservative selection is particularly sensitive. A preservative-free presentation is generally preferred for intrathecal administration unless the applicable regulatory framework expressly supports another approach.

How does excipient selection affect Lioresal product development?

Excipient selection affects four commercial variables: manufacturability, patient acceptance, regulatory risk, and product positioning.

Development objective	Excipient strategy	Commercial value	Main risk
Reduce tablet size	Higher-functionality filler and optimized compression aid	Easier swallowing; lower material use	Poor content uniformity or tablet strength
Improve disintegration	Crospovidone, croscarmellose, or optimized starch system	Faster tablet breakup	Moisture sensitivity
Remove lactose	Lactose-free formulation	Access for lactose-intolerant patients and institutional buyers	Compression and dissolution changes
Improve pediatric use	Palatable solution or mini-tablet	Dosing flexibility and adherence	Stability and taste-masking burden
Extend shelf life	Moisture-control packaging and robust excipients	Lower returns and broader distribution	Packaging cost
Support low-dose accuracy	Dilution strategy and blend uniformity controls	Better 5 mg performance	Segregation during manufacture
Avoid preservatives	Preservative-free multidose or unit-dose design	Advantage in sensitive populations	Microbial-control burden

The 5 mg strength is particularly important for titration and dose adjustment. A low-dose tablet must maintain content uniformity despite the relatively small quantity of baclofen. Direct compression can be efficient, but granulation may produce better blend uniformity and tablet robustness depending on the selected diluent and process.

What formulations are protected by patents for Lioresal?

The original baclofen compound and conventional oral tablet technology are not meaningful current exclusivity barriers in the United States. Commercial protection is more likely to arise from formulation patents, device patents, manufacturing know-how, trademarks, and regulatory exclusivities tied to a specific product.

Potentially protectable concepts include:

• Taste-masked baclofen oral liquids
• Stable baclofen suspensions
• Extended-release oral dosage forms
• Orally disintegrating tablets
• Multiparticulate or sprinkle formulations
• Unit-dose liquid presentations
• Preservative-free multidose systems
• Baclofen pump formulations and container closures
• Pump-compatible concentration and delivery systems
• Manufacturing processes that improve dose uniformity or impurity control

Patentability depends on claim scope, prior art, enablement, written description, and unexpected technical effects. A simple substitution of one conventional tablet excipient for another is unlikely to create a durable patent position without demonstrated performance advantages.

When does Lioresal lose exclusivity?

Lioresal’s conventional oral baclofen market has already lost effective market exclusivity. Generic baclofen tablets have been available for many years, and the original small-molecule patent estate does not prevent routine generic competition.

The relevant commercial timeline is therefore:

Exclusivity element	Current commercial implication
Baclofen composition of matter	Expired or commercially irrelevant
Conventional oral tablets	Generic competition established
Oral solution	Competition depends on product-specific approvals and supply
Intrathecal baclofen	Specialist competition; regulatory and manufacturing barriers remain
New formulation	Potential protection through new patents, regulatory exclusivity, or trade secrets
Delivery pump system	Device and combination-product rights may remain relevant

FDA exclusivity is product-specific. A new dosage form, route, or formulation can receive a separate regulatory review, but approval does not automatically create broad exclusivity for baclofen itself [3].

What is the Orange Book status of Lioresal and baclofen?

The Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity. Conventional generic baclofen tablets are generally evaluated through abbreviated new drug applications. A sponsor pursuing an oral baclofen product must assess the relevant reference-listed drug, dosage form, strength, labeling, and bioequivalence requirements [3].

For a new formulation, the regulatory route may differ:

• An ANDA may be appropriate for a product that is therapeutically equivalent to an approved reference product.
• A 505(b)(2) application may be appropriate when the sponsor relies partly on published data or an approved product but introduces a meaningful change, such as a new dosage form, concentration, or route.
• A full NDA may be required where the product cannot rely sufficiently on an approved reference or prior findings.

Orange Book patent status must be checked against the current FDA listing and the relevant reference product. Patent status can change through delisting, expiration, litigation, or settlement.

Are Paragraph IV challenges relevant to baclofen?

Paragraph IV litigation risk is generally limited for standard baclofen tablets because the market is mature and multiple generic products already exist. It remains relevant when a company develops a newly approved formulation or challenges patents listed for a branded modified-release, liquid, intrathecal, or combination product.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. The principal commercial consequences can include:

• A 45-day period for the patent owner to file suit
• A potential 30-month stay of FDA approval under applicable conditions
• First-filer dynamics for certain ANDA products
• Settlement restrictions under antitrust and Hatch-Waxman principles
• Delayed launch despite technical readiness

For a new baclofen product, the patent analysis should separate active ingredient claims from formulation, method-of-use, device, and manufacturing claims. The latter categories are more likely to affect launch timing.

Which companies are challenging Lioresal or competing in baclofen?

The competitive landscape is fragmented. Generic oral baclofen is supplied by multiple manufacturers, while intrathecal products are supplied by specialist injectable-drug companies and device-linked businesses. Competition typically occurs on:

• Wholesale acquisition cost
• Supply continuity
• Tablet strength availability
• Oral-liquid availability
• Hospital contract terms
• Pump compatibility
• Sterile manufacturing capacity
• Regulatory track record

The market does not have the same concentrated biosimilar dynamics seen with biologics. Baclofen is a small molecule, so biosimilar pathways do not apply. The relevant competitors are generic drug manufacturers, specialty injectable companies, compounding pharmacies where legally permitted, and device manufacturers involved in intrathecal pump systems.

What licensing deals and commercial partnerships affect Lioresal?

The most relevant partnership opportunities are not licenses to baclofen itself. They are commercial arrangements involving:

• Contract manufacturing of oral liquids
• Sterile fill-finish for intrathecal baclofen
• Pump-device compatibility
• Regional distribution rights
• Pediatric formulation development
• Hospital and specialty-pharmacy channels
• Packaging and dosing-device technology
• Co-development of extended-release products

A formulation owner could license a taste-masked liquid or modified-release technology to a generic manufacturer with established regulatory and commercial infrastructure. An injectable manufacturer could partner with a pump company or specialty distributor to secure access to spasticity centers.

No broad, current licensing structure is required to commercialize standard generic baclofen. Value is more likely to attach to differentiated formulation know-how, manufacturing capacity, or distribution access.

What patent litigation affects Lioresal and baclofen?

Routine oral baclofen is unlikely to generate material current patent litigation because the product is mature and heavily genericized. Litigation risk is higher for:

• Newly approved extended-release baclofen
• Patented oral-liquid technologies
• Intrathecal formulations with device-linked claims
• Pump systems and refill protocols
• Method-of-use claims involving specific patient populations
• Manufacturing patents that cover impurity control or sterile processing

A litigation review should search federal district court dockets, the Federal Circuit, FDA Orange Book entries, and patent assignment records. Product-specific litigation cannot be inferred from the existence of a baclofen patent alone.

What commercial opportunities exist for Lioresal excipient innovation?

Pediatric and neurologic-care formulations

Children with spasticity may require small, flexible doses. A palatable oral liquid with accurate dosing and a reliable oral syringe can address a practical gap. The excipient strategy should prioritize low bitterness, low viscosity variability, microbial control, and compatibility with feeding tubes.

Geriatric and dysphagia products

An orally disintegrating tablet, mini-tablet, or sprinkle formulation could improve administration for patients with swallowing difficulty. The product must maintain dose uniformity and avoid rapid environmental moisture uptake.

Excipient-reduced products

A formulation with fewer excipients may appeal to patients and institutions seeking allergen-controlled or intolerance-sensitive products. The commercial benefit is strongest if the product eliminates lactose, selected dyes, or unnecessary preservatives without sacrificing stability.

Extended-release baclofen

An extended-release formulation could reduce dosing frequency and smooth plasma exposure. The technical challenge is maintaining predictable release while limiting dose dumping and preserving efficacy across meals and gastrointestinal conditions. This category offers greater patent potential than conventional tablets.

Sterile intrathecal supply

Intrathecal baclofen has a smaller market but higher manufacturing barriers. Opportunities include ready-to-use presentations, improved container closure systems, validated pump compatibility, and reliable supply of approved concentrations. The regulatory burden is substantial, but the market is less exposed to routine tablet commoditization.

How strong is the patent estate for Lioresal?

The patent estate is weak for the original baclofen molecule and conventional immediate-release tablets. It can be moderate to strong for a genuinely differentiated product if claims cover:

1. A novel release architecture;
2. A demonstrated stability or palatability advantage;
3. A specific device or pump interface;
4. A manufacturing process that produces a measurable quality benefit; or
5. A formulation with clinically meaningful dosing or adherence advantages.

Trade secrets may be more important than patents for liquid manufacturing, taste masking, sterilization controls, and impurity management. Trade-secret value declines if the process can be readily reverse-engineered from the marketed product.

What generic launch risks exist for new baclofen products?

A generic or reformulated baclofen product faces several launch risks:

• Low pricing caused by mature tablet competition
• Limited physician switching incentives
• Pharmacy substitution rules
• Inadequate supply-chain scale
• Taste or dosing-device failure in oral liquids
• Sterility or particulate failures in intrathecal products
• Patent claims directed to formulation or delivery
• Regulatory classification disputes under ANDA versus 505(b)(2)
• Hospital purchasing pressure
• Low reimbursement for incremental formulation improvements

The highest-probability commercial strategy is a focused product with a clear operational advantage, not another undifferentiated immediate-release tablet.

How does Lioresal compare with competing baclofen products?

Attribute	Lioresal oral tablet	Generic baclofen tablet	Baclofen oral liquid	Intrathecal baclofen
Differentiation	Brand recognition	Price and supply	Administration flexibility	Route and severity of disease
Excipient opportunity	Limited	Limited	High	Moderate to high
Patent opportunity	Low for legacy product	Low	Moderate	Moderate
Manufacturing barrier	Low to moderate	Low to moderate	Moderate	High
Patient segment	General spasticity	General spasticity	Pediatric, geriatric, dysphagia	Severe refractory spasticity
Pricing power	Limited	Low	Moderate	Higher, subject to specialty competition
Regulatory complexity	Established	ANDA-focused	Stability and dosing-device issues	Sterile, device-linked

Key Takeaways

• Lioresal is a baclofen brand with no meaningful remaining composition-of-matter protection for conventional oral products.
• Excipient innovation is commercially relevant mainly in oral liquids, pediatric dosage forms, orally disintegrating products, modified-release systems, and intrathecal presentations.
• Standard baclofen tablets are highly commoditized and offer limited pricing power.
• The strongest formulation opportunities combine excipient differentiation with a practical patient or caregiver benefit.
• Intrathecal baclofen has higher technical and manufacturing barriers than oral tablets.
• Baclofen is a small molecule, so biosimilar competition does not apply.
• Paragraph IV risk is most relevant to newly patented dosage forms, delivery systems, and reformulated products.
• Manufacturing know-how, sterility assurance, packaging, and dosing devices may provide greater commercial value than legacy Lioresal patents.

FAQs

Is Lioresal the same as baclofen?

Yes. Lioresal is a brand of baclofen. Therapeutic equivalence depends on the approved dosage form, strength, route, formulation, and applicable regulatory requirements.

Can lactose-free baclofen be commercialized?

Yes. A lactose-free baclofen product can be developed if it satisfies quality, dissolution, stability, bioequivalence, and labeling requirements. The main commercial opportunity is in patients with lactose intolerance or excipient sensitivities.

Is there a commercial opportunity for baclofen oral suspension?

Yes. The opportunity is strongest where patients need flexible dosing, cannot swallow tablets, use feeding tubes, or require pediatric administration. Taste masking, sedimentation control, microbial stability, and dosing accuracy determine product quality.

Are there baclofen biosimilars?

No. Baclofen is a chemically synthesized small molecule. Competition is based on generic drug approval pathways, not biosimilar approval.

Can an extended-release baclofen product obtain patent protection?

Potentially. Protection depends on whether the release system, formulation, manufacturing process, or clinical performance is novel and non-obvious. A conventional excipient substitution alone is unlikely to support a durable patent position.

References

1. U.S. Food and Drug Administration. (2023). Lioresal Intrathecal baclofen injection prescribing information.
2. U.S. National Library of Medicine. (2024). DailyMed: Baclofen product labeling.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
5. United States Pharmacopeia. (2024). USP-NF general chapters and standards for oral and parenteral dosage forms.